Eric Kelsic News Today

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...

Scientists at Harvard Medical School and Technion-Israel Institute of Technology have built a giant petri dish to visually demonstrate how bacteria move as they become immune to drugs.

Published May 6, 2021 Permission granted by Eric Kelsic / Dyno Therapeutics Dyno Therapeutics, a Harvard University spinout working to improve gene therapy, is expanding with $100 million in new funding from tech investor Andreessen Horowitz and several other venture firms. Since officially launching a year ago, Dyno has struck deals with Novartis, Roche and Sarepta Therapeutics to aid their efforts to develop more efficient delivery of ge...

Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing. The round was led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. As part of the Series A financing, Jorge Conde, General Partner at Andreessen H...

MedCity News Andreessen Horowitz leads $100M Series A round in Dyno and its gene therapy tech Dyno Therapeutics’ technology for designing viral vectors that deliver gene therapies has led to partnerships with Novartis, Sarepta Therapeutics, and Roche. With the Series A financing, the startup plans to expand its technology to address more tissue types, and potentially add more partners. Shares0 Improved AAV vector capsid for gene therapy engineered with a new machine-guided approach shows, i...

Dyno raises $100 million to bring artificial intelligence to gene therapy By Anissa Gardizy Globe Staff,Updated May 6, 2021, 11:21 a.m. Email to a Friend Dyno Therapeutics chief executive Eric Kelsic.Courtesy of Dyno Therapeutics Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence to develop gene therapies, said Thursday that it has raised $100 million from investors. The company uses machine learning to design a type of gene therapy “vector” — or carrier �...

 E-Mail IMAGE: In their machine learning-based capsid diversification strategy, the team focused on a 28 amino acid peptide within a segment of the AAV2 VP3 capsid protein that exposes the AAV capsid... view more  Credit: Wyss Institute at Harvard University (original by Drew Bryant) (Boston) -- Adeno-associated viruses (AAVs) have become promising vehicles for delivering gene therapies to defective tissues in the human body because they are non-pathogenic and can transfer therapeutic D...